William Blair Cuts Earnings Estimates for Beam Therapeutics

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at William Blair decreased their Q2 2025 earnings estimates for shares of Beam Therapeutics in a research report issued on Tuesday, May 6th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($1.01) per share for the quarter, down from their previous forecast of ($0.94). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. William Blair also issued estimates for Beam Therapeutics’ Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($4.09) EPS, Q1 2026 earnings at ($0.94) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.91) EPS.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.13). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business had revenue of $7.47 million for the quarter, compared to analyst estimates of $14.69 million. During the same period in the previous year, the firm posted ($1.21) earnings per share. The firm’s quarterly revenue was up 1.4% on a year-over-year basis.

Several other research firms have also weighed in on BEAM. Guggenheim dropped their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday. Royal Bank of Canada upped their price target on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 26th. Wells Fargo & Company reduced their price objective on Beam Therapeutics from $75.00 to $70.00 and set an “overweight” rating for the company in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Beam Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reiterated an “outperform” rating and set a $57.00 price target on shares of Beam Therapeutics in a report on Monday, March 10th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $48.75.

Beam Therapeutics Price Performance

NASDAQ:BEAM opened at $17.42 on Friday. The stock’s 50-day moving average is $20.07 and its two-hundred day moving average is $24.32. The stock has a market cap of $1.75 billion, a PE ratio of -9.90 and a beta of 2.35. Beam Therapeutics has a fifty-two week low of $13.53 and a fifty-two week high of $35.25.

Hedge Funds Weigh In On Beam Therapeutics

A number of institutional investors have recently made changes to their positions in BEAM. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Beam Therapeutics in the 4th quarter valued at approximately $330,000. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Beam Therapeutics by 11.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock worth $98,149,000 after acquiring an additional 404,782 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of Beam Therapeutics by 18.4% in the fourth quarter. Teacher Retirement System of Texas now owns 20,767 shares of the company’s stock worth $515,000 after acquiring an additional 3,222 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Beam Therapeutics by 3.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 648,945 shares of the company’s stock worth $16,094,000 after acquiring an additional 19,453 shares during the period. Finally, Avanza Fonder AB acquired a new position in Beam Therapeutics during the 4th quarter valued at $1,247,000. 99.68% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, President Giuseppe Ciaramella sold 7,434 shares of Beam Therapeutics stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $136,413.90. Following the transaction, the president now owns 190,216 shares in the company, valued at $3,490,463.60. This trade represents a 3.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Christine Bellon sold 5,674 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $104,117.90. Following the sale, the insider now owns 117,294 shares of the company’s stock, valued at $2,152,344.90. This trade represents a 4.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,771 shares of company stock valued at $803,198 over the last 90 days. 4.20% of the stock is currently owned by company insiders.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.